Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Value-Added Medicines

Set Alert for Value-Added Medicines

Alvogen Strikes Deals For Pfenex’ Teriparatide

Alvogen has signed marketing deals with local firms in Canada, Israel and South Korea for the teriparatide drug it has licensed from Pfenex. In the US, Pfenex has just completed a human factors study it feels should support a therapeutic equivalence rating for its Forteo rival.

Deals Value-Added Medicines

Value Added Medicines Hold Promise Despite Challenges

An IQVIA report dives into how technology can facilitate a digital future for value added medicines, while discussing the market size, opportunities, scope of growth and challenges for this emerging sector in healthcare.

Value-Added Medicines Market Intelligence

Early Dialogue And Patient Involvement Can Unlock Value

Recognizing the benefits of value added medicines in European hospital settings can help patients and healthcare professionals, a KPMG report commissioned by Medicines for Europe suggests.

Value-Added Medicines Europe

Stoller Sets Agenda As Medicines For Europe’s President

Christoph Stoller, Teva’s general manager for Germany and Austria, has just been announced as president of European off-patent industry association Medicines for Europe with a two-year mandate. In an exclusive interview, he sets out the organization’s immediate priorities.

Appointments Europe

Shortlist Revealed For Industry Awards

Shortlists for each of the 14 categories in the Global Generics & Biosimilars Awards 2019 have been announced, after our panel of expert judges considered almost 100 entries.

Generic Drugs Biosimilars

US Study Lends Support To Polypill Proposals

Fixed-dose polypills containing commonly available generic cardiovascular agents could cut risks in low-income populations within the US, a randomized clinical trial suggests.

Cardiovascular Clinical Trials
See All